Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TML-6 in healthy volunteers
NCT06562114Phase 1Completed
- Sponsor
- Merry Life Biomedical Co., Ltd.
- Start
- Jul 2024
- Primary completion
- Jul 2025
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, randomised trial comparing TML-6 Granules with Placebo (2 arms). Primary endpoints: Serious Adverse Events and Treatment-Related Adverse Events. Started Jul 2024; status: completed.
02
Drugs
TML-6
Beyond the preview
Go deeper on NCT06562114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06562114.